Literature DB >> 11748164

Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Barbara Papadopoulou1, Gaétan Roy, Marie Breton, Christoph Kündig, Carole Dumas, Isabelle Fillion, Ajay K Singh, Martin Olivier, Marc Ouellette.   

Abstract

Pterins are essential for the growth of Leishmania species, and recent work has led to the isolation of the biopterin transporter BT1. In this study, we inactivated the Leishmania donovani biopterin transporter BT1 by gene disruption mediated by homologous recombination. No transport of biopterin was detected in this mutant. The L. donovani BT1 null mutant showed a much lesser capacity for inducing infection in mice than wild-type parasites and could elicit protective immunity in mice susceptible to infection against a L. donovani challenge. Splenocytes isolated from mice immunized with the BT1 null mutant parasites produced significant amounts of interferon gamma following stimulation with L. donovani promastigotes as measured by enzyme-linked immunosorbent assay and enzyme-linked immunospot assays. Overall, these results show that by genetically manipulating the pterin transport in L. donovani, it is possible to generate an attenuated organism that could be part of a vaccination strategy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748164      PMCID: PMC127620          DOI: 10.1128/IAI.70.1.62-68.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites.

Authors:  M Ouellette; E Leblanc; C Kündig; B Papadopoulou
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

2.  Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.

Authors:  V S Dole; V S Raj; A Ghosh; R Madhubala; P J Myler; K D Stuart
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

3.  Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin.

Authors:  M L Cunningham; R G Titus; S J Turco; S M Beverley
Journal:  Science       Date:  2001-04-13       Impact factor: 47.728

4.  The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.

Authors:  J Lehmann; K H Enssle; I Lehmann; A Emmendörfer; M L Lohmann-Matthes
Journal:  J Interferon Cytokine Res       Date:  2000-01       Impact factor: 2.607

5.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

Review 6.  Cytokine-producing T cell subsets in human leishmaniasis.

Authors:  K Kemp
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

Review 7.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

8.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.

Authors:  K E Squires; R D Schreiber; M J McElrath; B Y Rubin; S L Anderson; H W Murray
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

10.  Plasticity in chromosome number and testing of essential genes in Leishmania by targeting.

Authors:  A K Cruz; R Titus; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

View more
  33 in total

1.  Episomally driven antisense mRNA abrogates the hyperinducible expression and function of a unique cell surface class I nuclease in the primitive trypanosomatid parasite, Crithidia luciliae.

Authors:  Mat Yamage; Manju B Joshi; Dennis M Dwyer
Journal:  J Mol Biol       Date:  2007-08-21       Impact factor: 5.469

2.  Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Pragya Misra; Sujoy Dutta; Bala Krishna Kolli; Sharad Sharma; Kwang Poo Chang; Anuradha Dube
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

3.  UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.

Authors:  Siddhartha Kumar Bhaumik; Manoj Kumar Singh; Subir Karmakar; Tripti De
Journal:  Glycoconj J       Date:  2008-11-13       Impact factor: 2.916

4.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence.

Authors:  Ranadhir Dey; Claudio Meneses; Poonam Salotra; Shaden Kamhawi; Hira L Nakhasi; Robert Duncan
Journal:  Mol Microbiol       Date:  2010-05-24       Impact factor: 3.501

6.  Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.

Authors:  Kevin W Bruhn; Ron Birnbaum; Jacquelyn Haskell; Veena Vanchinathan; Stephanie Greger; Rupa Narayan; Pei-Lin Chang; Thu Anh Tran; Suzanne M Hickerson; Stephen M Beverley; Mary E Wilson; Noah Craft
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

7.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

8.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  A Leishmania-specific gene upregulated at the amastigote stage is crucial for parasite survival.

Authors:  Kumar Avishek; Kavita Ahuja; Dibyabhaba Pradhan; Sreenivas Gannavaram; Angamuthu Selvapandiyan; Hira L Nakhasi; Poonam Salotra
Journal:  Parasitol Res       Date:  2018-08-14       Impact factor: 2.289

Review 10.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.